Fig. 9: Variation in outcome estimation based on stromal TIL assessment.
From: Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Shown is the variation in estimated outcome based on sTIL assessment for a 60-year-old patient with a histological grade 3 tumor, 2–5cm in size and receiving anthracycline+taxane based chemotherapy. Presuming a true value for sTILs of 30%, changes in estimated 5-year iDFS for 5, 10, and 20% deviations (increase and decrease) in sTIL assessments are represented with 95% confidence bands. (All calculations were performed using the online triple-negative breast cancer (TNBC)-prognosis tool9 available at www.tilsinbreastcancer.org).
